Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products AHMEDABAD, India and SOLANA ...

Sentynl will acquire full rights to Progerinin for HGPS, provided certain milestones are achieved.

Zydus Lifesciences' subsidiary, Sentynl Therapeutics, has licensed the experimental molecule Progerinin to treat ...

Life is short—especially for children with Hutchinson-Gilford progeria syndrome, a rare disease in which individuals rapidly develop symptoms of old age, such as hair loss, wrinkled skin, arthritis ...

JOHANNESBURG (AP) — The elfin child with the big personality and bright smile calls herself “the first lady” and dreams of the future. But doctors say 12-year-old Ontlametse Phalatse has only, perhaps ...